Open-Label, Single-Center, Phase I/Ⅱ Clinical Trial to Evaluate the Safety and the Efficacy of Exosomes Derived From Allogenic Adipose Mesenchymal Stem Cells in Patients With Mild to Moderate Dementia Due to Alzheimer's Disease
Latest Information Update: 22 Apr 2025
At a glance
- Drugs Mesenchymal stem cell based exosome therapy-AbelZeta-Pharma (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions
Most Recent Events
- 23 Jun 2021 Planned End Date changed from 1 Apr 2022 to 1 Aug 2022.
- 23 Jun 2021 Planned primary completion date changed from 1 Apr 2021 to 1 Aug 2021.
- 26 Sep 2020 Status changed from not yet recruiting to recruiting.